KRAS and melanoma: Among their most interesting observations was that out of 32 non-acral melanoma samples genotyped for a KRAS oncogene variant located in the 3′ untranslated region (3′UTR) and known to be affecting the binding site for miRNAs, 25% were positive for the KRAS-variant, thus suggesting the association of this variant with the increased risk of developing melanomas.